Suppr超能文献

白血病儿童和青少年接受匹配或不匹配的无关供者或部分匹配的相关供者骨髓进行部分T细胞清除后的移植结果。

Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias.

作者信息

Bunin N, Aplenc R, Leahey A, Magira E, Grupp S, Pierson G, Monos D

机构信息

Division of Oncology, The Children's Hospital of Philadelphia, 34th and Civic Center Blvd., Philadelphia, PA 19104, USA.

出版信息

Bone Marrow Transplant. 2005 Jan;35(2):151-8. doi: 10.1038/sj.bmt.1704754.

Abstract

Graft-versus-host disease (GVHD) remains a major barrier to successful hematopoietic stem cell transplant for patients who lack a matched related donor. Partial T-cell depletion (TCD) of the graft may decrease the risk of severe GVHD with unrelated donors (URD) and partially matched related donors (PMRD) while retaining an antileukemic effect. We analyzed our experience using URD and PMRD for pediatric patients with leukemias from 1990 to 2001. A subgroup of 'matched' URD donor pairs was retrospectively analyzed for high-resolution class I. Partial TCD was accomplished with monoclonal antibody T10B9 or OKT3 and complement. There were 76 URD (45% matched) and 28 PMRD recipients. Event-free survival (EFS) was 38.3%, and overall survival (OS) 45.1% at 3 years. On multivariate analysis, there was no difference in survival based upon marrow source, but nonrelapse mortality was higher with the use of PMRD. Relapse occurred in 6% of ALL patients, and 22.8% of AML/MDS patients. Grades III-IV GVHD was observed in only 6.7% of patients. Partial TCD allows use of matched or mismatched URD, or PMRD with little mortality from GVHD, durable engraftment, and no increase in relapse risk.

摘要

对于缺乏匹配的相关供体的患者而言,移植物抗宿主病(GVHD)仍然是成功进行造血干细胞移植的主要障碍。对移植物进行部分T细胞清除(TCD)可能会降低使用无关供体(URD)和部分匹配的相关供体(PMRD)时发生严重GVHD的风险,同时保留抗白血病效应。我们分析了1990年至2001年期间使用URD和PMRD治疗小儿白血病患者的经验。对一组“匹配的”URD供体对进行回顾性高分辨率I类分析。使用单克隆抗体T10B9或OKT3及补体完成部分TCD。共有76例URD受者(45%匹配)和28例PMRD受者。3年时无事件生存率(EFS)为38.3%,总生存率(OS)为45.1%。多因素分析显示,基于骨髓来源的生存率无差异,但使用PMRD时非复发死亡率更高。急性淋巴细胞白血病(ALL)患者的复发率为6%,急性髓细胞白血病/骨髓增生异常综合征(AML/MDS)患者的复发率为22.8%。仅6.7%的患者观察到III-IV级GVHD。部分TCD允许使用匹配或不匹配的URD或PMRD,GVHD导致的死亡率低,植入持久,且复发风险不增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验